|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
2
|
|
pubmed:dateCreated |
2008-2-25
|
|
pubmed:abstractText |
To evaluate pathological complete response rate and to identify the predictor of response after primary systemic chemotherapy (PST) with weekly docetaxel and epirubicin for locally advanced breast cancer.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antibiotics, Antineoplastic,
http://linkedlifedata.com/resource/pubmed/chemical/Antineoplastic Agents, Phytogenic,
http://linkedlifedata.com/resource/pubmed/chemical/Cyclophosphamide,
http://linkedlifedata.com/resource/pubmed/chemical/Epirubicin,
http://linkedlifedata.com/resource/pubmed/chemical/Fluorouracil,
http://linkedlifedata.com/resource/pubmed/chemical/Receptor, erbB-2,
http://linkedlifedata.com/resource/pubmed/chemical/Taxoids,
http://linkedlifedata.com/resource/pubmed/chemical/Tumor Markers, Biological,
http://linkedlifedata.com/resource/pubmed/chemical/docetaxel
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Feb
|
|
pubmed:issn |
1465-3621
|
|
pubmed:author |
pubmed-author:ChangHsien-KunHK,
pubmed-author:ChenMiin-FuMF,
pubmed-author:ChenShin-ChehSC,
pubmed-author:CheungYun-ChungYC,
pubmed-author:HsuehSweiS,
pubmed-author:LeungWai-ManWM,
pubmed-author:LinYung-ChangYC,
pubmed-author:LoYung-FengYF,
pubmed-author:ShenShih-CheSC,
pubmed-author:TsaiChien-ShengCS,
pubmed-author:TsaiHsiu-PeiHP
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
38
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
99-105
|
|
pubmed:dateRevised |
2009-11-19
|
|
pubmed:meshHeading |
pubmed-meshheading:18270380-Adult,
pubmed-meshheading:18270380-Aged,
pubmed-meshheading:18270380-Analysis of Variance,
pubmed-meshheading:18270380-Antibiotics, Antineoplastic,
pubmed-meshheading:18270380-Antineoplastic Agents, Phytogenic,
pubmed-meshheading:18270380-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:18270380-Breast Neoplasms,
pubmed-meshheading:18270380-Chemotherapy, Adjuvant,
pubmed-meshheading:18270380-Cyclophosphamide,
pubmed-meshheading:18270380-Drug Administration Schedule,
pubmed-meshheading:18270380-Electrocardiography,
pubmed-meshheading:18270380-Epirubicin,
pubmed-meshheading:18270380-Female,
pubmed-meshheading:18270380-Fluorouracil,
pubmed-meshheading:18270380-Humans,
pubmed-meshheading:18270380-Infusions, Intravenous,
pubmed-meshheading:18270380-Injections, Intravenous,
pubmed-meshheading:18270380-Middle Aged,
pubmed-meshheading:18270380-Neoadjuvant Therapy,
pubmed-meshheading:18270380-Neoplasm Staging,
pubmed-meshheading:18270380-Predictive Value of Tests,
pubmed-meshheading:18270380-Receptor, erbB-2,
pubmed-meshheading:18270380-Stroke Volume,
pubmed-meshheading:18270380-Taxoids,
pubmed-meshheading:18270380-Treatment Outcome,
pubmed-meshheading:18270380-Tumor Markers, Biological,
pubmed-meshheading:18270380-Ultrasonography, Mammary,
pubmed-meshheading:18270380-Up-Regulation,
pubmed-meshheading:18270380-Ventricular Function, Left
|
|
pubmed:year |
2008
|
|
pubmed:articleTitle |
High pathologic complete response in HER 2-positive locally advanced breast cancer after primary systemic chemotherapy with weekly docetaxel and epirubicin.
|
|
pubmed:affiliation |
Department of Surgery, Chang-Gung Memorial Hospital, 199, Tung-Hwa North Road, Taipei, Taiwan. chensc@adm.cgmh.org.tw
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial, Phase II
|
